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Abstract: The vacuolar (H+)-ATPases that pump H+ from the cytoplasm to extracellular compartments can alter the pH of the tumor
microenvironment. Esomeprazole can effectively inhibit vacuolar (H+)-ATPases and may increase the effectiveness of chemotherapeutics.
Therefore, we used esomeprazole in combination with cisplatin, carboplatin, paclitaxel, docetaxel, gemcitabine, and vinorelbine on the
A549 nonsmall-cell lung cancer cell line. Cisplatin and carboplatin combinations with esomeprazole exhibited superior cytotoxicity
compared to the other selected chemotherapeutics. Low-dose combinations of esomeprazole with either cisplatin or carboplatin
resulted in synergistic interaction. We examined cytotoxic activity of these combinations with the xCELLigence real-time cytotoxicity
assay and detected that esomeprazole combinations with both 100% test drug concentrations of cisplatin and carboplatin shifted the
antiproliferative effects of these agents towards a cytotoxic effect in a dose-dependent manner. Cell death mode was investigated by
M30 assay, Annexin-V-FITC fluorescence imaging, and determination of PARP cleavage in western blotting. The cells treated with the
cisplatin and esomeprazole combination displayed characteristic features of apoptosis such as elevated M30 levels, Annexin-V staining,
and PARP cleavage. In conclusion, these novel combinations resulted in higher sensitivity of tumors to chemotherapeutics, thereby
warranting further in vivo experiments for proof of the concept.
Key words: Lung carcinoma, cisplatin, carboplatin, esomeprazole, apoptosis, synergism

1. Introduction
Lung cancer ranks first in deaths among malignancies
and approximately 1.59 million people (19.4% of all
cancer deaths excluding nonmelanoma skin cancer)
die worldwide from lung cancer every year (Ferlay et
al., 2013). The 5-year survival rate for nonsmall-cell
lung cancer is estimated to be 10.5% for females and
9.4% for males (Caldarella et al., 2007). No symptoms
are detected in the early stage of most lung cancer cases,
which results in late diagnosis (Carter-Harris et al.,
2014; Shim et al., 2014). Despite the recently developed
diagnostic methods, the localization of detected tumors
is not limited to the lungs. The most important difficulty
in lung cancer therapy is metastasis to different organs
or different sites in the lung, which makes it almost
impossible to fully eradicate the tumor by surgery,
radiotherapy, and chemotherapy. Hence, resistance to
chemotherapeutics becomes crucial in patients with no
chance of curative surgery.
* Correspondence: eulukaya@uludag.edu.tr

The acidity of the tumor microenvironment is one
of the important factors in chemotherapy resistance.
The vacuolar (H+)-ATPases (V-ATPases) that pump H+
from the cytoplasm to extracellular compartments have
a critical role in acidity (Perez-Sayans et al., 2009). These
multisubunit V-ATPase complexes are basically expressed
in all eukaryotic cells, although there are variations
in subunits (Wagner et al., 2004). However, they are
preferentially expressed in various cancer types including
pancreatic cancer, oral squamous cell cancer, and
nonsmall-cell lung carcinoma compared to nonmalignant
tissues, and higher expression levels of V-ATPases are
linked to malignant phenotypes (Sennoune et al., 2004;
Chung et al., 2011; Garcia-Garcia et al., 2012; Qiang et al.,
2013). Consequently, therapeutic approaches to inhibit
V-ATPases are expected to increase sensitivity towards
antineoplastic agents or overcome chemoresistance.
Tumor tissues, and especially solid tumors, possess
different microenvironmental features (Vaupel, 2004). The
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tumor vasculature system is irregular and bears anomalies
with the effect of growth factors, and there are no lymphatics
present in the tumor tissue (Leu et al., 2000; Padera et al.,
2002). The most important factor contributing to the acidic
tumor microenvironment is adaptation to the glycolytic
phenotype resulting from the induction of hypoxiainducible factor 1α that leads to lactate production during
anaerobic glucose metabolism (Gatenby and Gillies,
2004). The pH of solid tumors was observed to be more
acidic than that of normal tissues when measured directly
with electrodes (Van Den Berg et al., 1982). Hypoxic and
acidic tumor microenvironments enable the selection of
cells in this unfavorable environment that triggers the
transformation from a benign to a malignant phenotype.
It has been shown that acidity takes part in chemotherapy
resistance, proliferation, and metastatic transformation
(Morita et al., 1992; Martinez-Zaguilan et al., 1996;
Raghunand et al., 2001).
The acidic tumor microenvironment can have a
critical role in chemotherapy resistance (Simon et al.,
1994; Mahoney et al., 2003). Some of the mechanisms
of chemotherapy resistance resulting from an acidic
microenvironment include decreased drug intake,
neutralization of weakly basic drugs, and sequestration of
drugs into lysosomal vesicles (Simon et al., 1994; MartinezZaguilan et al., 1999; Raghunand et al., 1999b, 2003).
Proton pump inhibitors (PPIs) inhibit H+/K+ ATPase
function, the last step of acid secretion in parietal cells.
The most potent gastric acid secretion-inhibiting PPIs in
clinical use are omeprazole, lansoprazole, pantoprazole,
rabeprazole, and esomeprazole (Shi and Klotz, 2008).
Esomeprazole, an S-enantiomer of omeprazole used in our
study, decreases gastric acid secretion with a distinctive
mechanism of action (Robinson, 2001). It was shown
that PPIs effectively inhibit V-ATPases in vitro, increase
chemotherapy efficacy, and are well tolerated in studies
with rat and mouse models (Luciani et al., 2004; De Milito
et al., 2007, 2010). There is also a phase I clinical study that
involves concomitant use of pantoprazole and doxorubicin
in advanced solid tumors (Brana et al., 2014).
In this study, it was aimed to investigate whether
esomeprazole alters the chemosensitivity of A549,
a nonsmall-cell lung carcinoma line, to traditional
chemotherapeutic agents used in lung cancer therapy.
For this purpose, combinations of esomeprazole with
cisplatin, carboplatin, paclitaxel, docetaxel, gemcitabine,
or vinorelbine were used and their cytotoxic effects were
investigated with several methods.
2. Materials and methods
2.1. Cell culture
The A549 human lung cancer cell line was cultured
using Ham’s F12 without L-glutamine (Pan Biotech,
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Aidenbach, Germany) in the presence of 10% newborn
calf serum (HyClone, USA), 1% penicillin G (100 U/mL)/
streptomycin (100 µg/mL) (HyClone), and 1% L-glutamine
(292.3 mg/L) (EuroClone, Italy) at 37 °C in a humidified
atmosphere containing 5% CO2.
2.2. Drugs and experimental groups
All drugs were used at 6.25%, 12.5%, 25%, 50%, 100%,
and 200% test drug concentrations (% TDCs) and
diluted in cell culture media. A level of 100% TDC is the
approximate level of plasma peak concentrations of the
chemotherapeutics (Andreotti et al., 1995). Esomeprazole
sodium salt (Nexium, AstraZeneca, Turkey) was
resuspended in 5 mL of 0.9% NaCl before use and used
in 62.5 µM, 125 µM, and 250 µM final concentrations.
The anticancer drugs used in the experiments were as
follows: cisplatin (100% TDC = 7.6 µg/mL, Cisplatin,
Koçak Farma, Turkey), carboplatin (100% TDC = 15.8 µg/
mL, Carboplatin, Eczacıbaşı, Turkey), paclitaxel (100%
TDC =13.6 µg/mL, Taxol, Bristol-Myers Squibb, Turkey),
docetaxel (100% TDC =11.3 µg/mL, Taxotere, SanofiAventis, Turkey), gemcitabine (100% TDC = 25 µg/mL,
Gemzar, Lilly, Turkey), and vinorelbine (100% TDC =1.86
µg/mL, Navelbine, Pierre Fabre, Turkey).
2.3. The MTT assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) cell viability assay was performed as
previously described (Ulukaya et al., 2008). A549 cells
were seeded at a density of 5 × 103 cells per well of a 96well plate in 200 µL of culture medium. Two independent
experiments, with each run in triplicate, were performed.
The cells were treated for 72 h with different concentrations
of esomeprazole, and for the combination treatments,
the cells were incubated for 72 h with the drugs and
esomeprazole. In brief, at the end of the treatment period,
25 µL of MTT solution (5 mg/mL PBS, pH 7.2) was added
to each well. Following incubation for 4 h at 37 °C, 100
µL of the solubilizing buffer (10% SDS dissolved in 0.01 N
HCl) was added. Viability of treated cells was calculated in
reference to the untreated control cells using the following
formula: viability (%) = (100 × (sample Abs)/(control
Abs)), where Abs is the absorbance value at 570 nm.
2.4. Real-time cytotoxicity assay
The xCELLigence system (Roche, Germany) was operated
according to the instructions in the user manual. Following
the background impedance measurements, A549 cells (2.5
× 103 cells in 100 µL) were seeded in each well of an E-Plate
96 (Roche) to increase the final volume to 200 µL. After 60
min of incubation at 37 °C in the cell culture incubator, the
E-Plate 96 was placed into the system. Adhesion, growth,
and proliferation of the cells was monitored every 60 min
for up to 96 h via the incorporated sensor electrode arrays
of the E-Plate 96. Twenty-four hours after seeding, 100 µL
of medium was removed from the E-Plate 96 wells without
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damaging the cells. The cells were then exposed to 100
µL of medium containing different doses of cisplatin or
carboplatin alone (6.25%–100% TDC) or combined with
esomeprazole (62.5–250 µM). Only 100 µL of medium was
added to wells containing control cells. All experiments
were run for 96 h and a time-dependent cell index graph
was produced by the device using the real-time cytotoxicity
assay software of the manufacturer.
2.5. Detection of caspase-cleaved cytokeratin 18 (M30)
Apoptosis was assayed by measuring the level of caspasecleaved keratin 18 (ccK18, M30) with a commercially
available immunoassay kit (M30-Apoptosense ELISA
kit, Peviva AB, Sweden) according to the manufacturer’s
instructions. In the M30 ELISA assay, samples react
with the solid-phase capture antibody M5 and the HRPconjugated M30 antibody, which are directed against
K18 and the K18Asp396 neoepitope, respectively. The
neoepitope was exposed after caspase cleavage of K18 after
aspartic acid residue 396 (Leers et al., 1999). Cleavage at
this position occurs early during apoptosis by caspase
9 and during the execution phase by caspase-3 and -7
(Schutte et al., 2004). Cells were seeded at a rate of 1 × 104
per well of a 96-well plate in 200 µL of culture medium in
triplicates. Cells were treated for 48 h with esomeprazole
(250 µM), carboplatin (100% TDC), and cisplatin (100%
TDC) alone and carboplatin or cisplatin in combination
with esomeprazole. Two independent experiments were
carried out in triplicates. At the end of the treatment
period, the cells were lysed with 10% NP-40 for 10 min
on a shaker. The content of identical wells was pooled
and centrifuged at 2000 rpm for 10 s to remove the
debris. All samples were placed into wells coated with a
mouse monoclonal antibody as a catcher. After washing,
a horseradish peroxidase-conjugated antibody (M30) was
used for detection. The absorbance was determined with
an ELISA reader at 450 nm (FLASH Scan S12, Analytik
Jena, Germany) (Leers et al., 1999; Ueno et al., 2003).
2.6. Fluorescence microscopy
When apoptosis occurs, phosphatidylserine molecules
translocate to the outside of the cell membrane, which
is an early event in apoptotic cells. Annexin-V-FITC can
bind to phosphatidylserine, allowing the apoptotic cells
to be visible. A549 cells were seeded in a 96-well plate at
the density of 1 × 104 cells per well. The cells were treated
with 100% TDC cisplatin and carboplatin alone, 250 µM
esomeprazole alone, and its combination with 100% TDC
cisplatin or carboplatin for 12 h. After treatment, the cells
were stained with Annexin-V-FITC and propidium iodide
(PI) using the Annexin-V-FLUOS staining kit (Roche).
Annexin-V-FITC and PI were diluted (1:50) from stock
solution with incubation buffer to yield a working solution.
Hoechst dye 33342 (5 µg/mL final concentration) was
added to this solution as well to observe all alive and dead

cells. The cells were then incubated for 30 min at room
temperature after aspirating the medium and the addition
of 50 µL of working solution to each well. Apoptotic cells
were visualized under a fluorescence microscope.
2.7. SDS-PAGE and western blotting
A549 cells were seeded in 6-well plates (7.5 × 105 cells/
well) and incubated with different doses of esomeprazole
(62.5 µM, 125 µM, 250 µM) and cisplatin (100% TDC)
or carboplatin (100% TDC) combinations for 24 h. Cells
were scraped at the end of the treatment and washed with
ice-cold PBS. The cells were then lysed in RIPA lysis buffer
(Santa Cruz Biotechnology Inc., USA) containing protease
inhibitors. The proteins were extracted at 4 °C for 30 min
and centrifuged at 4 °C for 10 min at 10,000 × g. Equal
amounts of protein (30 µg protein/lane) were subjected
to 4%–12% gradient gel SDS-PAGE and then transferred
to a nitrocellulose membrane. Western blotting was
performed using rabbit anti-PARP monoclonal antibody
(1:1000 dilution; Cell Signaling, USA) and rabbit antiβ-actin monoclonal antibody (1:1000 dilution; Cell
Signaling). HRP-linked antirabbit IgG antibodies (1:2000
dilution; Cell Signaling) and LumiGLO reagent and
peroxide (Cell Signaling) were used to detect primary
antibodies according to the manufacturer’s instructions.
The membrane was stripped for subsequent detection.
Bound antibodies were visualized on a Fusion FX-7
imaging device (Vilber Lourmat, France). The bands were
quantified by using ImageJ 1.49v software.
2.8. Statistical evaluation
SPSS 22.0 was used for the statistical analysis. Comparison
of groups for each dose was examined by one-way analysis
of variance. Dunnett’s multiple comparison test was
used for testing the presence of statistical significance.
Differences were considered to be statistically significant
when P ≤ 0.05.
Combination index (CI) values were calculated using
CalcuSyn Version 2.1 according to the Chou–Talalay
method for drug combinations (Chou, 2010). The CI is a
parameter that gives information about the effectiveness
of drug combinations. Combination effects are defined as
very strong synergism (CI < 0.1), strong synergism (0.1 <
CI < 0.3), synergism (0.3 < CI < 0.7), moderate synergism
(0.70 < CI < 0.85), slight synergism (0.85 < CI < 0.90),
nearly additive (0.9 < CI < 1.1), and antagonistic (CI > 1.1)
(Chou, 2006).
3. Results
3.1. Cytotoxic activities of esomeprazole and
chemotherapeutics by the MTT assay
The cytotoxic effect of esomeprazole was investigated by
employing the MTT assay on A549 cells. We found that
esomeprazole treatment exhibited antigrowth effects in
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a dose-dependent manner at most of the doses (Figure
1). The dose of esomeprazole that inhibited 50% of the
cell proliferation (IC50) corresponded approximately
to 500 µM. A sublethal dose, 250 µM, was selected
for combination treatments since 500 µM might be
considered a suprapharmacological concentration. Drugs
that are frequently used in the treatment of lung cancer
(cisplatin, carboplatin, paclitaxel, docetaxel, gemcitabine,
vinorelbine) were combined with esomeprazole. It
was demonstrated that only carboplatin and cisplatin
combinations with esomeprazole led to apparent and
significant increases in cytotoxicity. On the other hand,
esomeprazole combinations with paclitaxel, docetaxel,
gemcitabine, and vinorelbine did not produce any
cytotoxic activity. Hence, only carboplatin, cisplatin, and
their combinations with esomeprazole were used for
further experiments.
Cell viability was measured with the MTT assay. It was
found that both carboplatin and cisplatin combinations
with esomeprazole decreased cell viability in a dosedependent manner (Figure 2). The decrease in % viability

was statistically significant at low doses of carboplatin
and cisplatin when combined with 250 µM esomeprazole
(P < 0.001). For the lowest dose of cisplatin, 6.25 TDC,
combination with 250 µM esomeprazole decreased %
viability dramatically whereas cisplatin alone and its
combinations with 62.5 and 125 µM esomeprazole were
ineffective (Figure 2). The growth inhibitory effects of 250
µM esomeprazole + carboplatin were significant at 6.25,
12.5, and 100 TDC. However, carboplatin combinations
with 62.5 and 125 µM esomeprazole did not result in a
higher efficacy (Figure 2).
We further examined if there were any synergistic,
additive, or antagonistic interactions between esomeprazole
and cisplatin or carboplatin. As we expected, the resulting
interaction in 250 µM esomeprazole combination with
cisplatin and carboplatin was synergism at all doses except
the 250 µM esomeprazole + 100% TDC carboplatin
combination, which was an additive interaction (Table).
In contrast, there was no synergistic interaction in 62.5
and 125 µM esomeprazole + cisplatin or carboplatin
treatments (data not shown).

MTT, 72 h

100

% viability

80
60
40
20
0

16

31

63
125
250
Esomeprazole (µM)

500

1000

Figure 1. A549 cells were incubated for 72 h with various
concentrations of esomeprazole and the % viabilities of the cells
were assayed using the MTT assay.

Figure 2. The % viability is shown after cisplatin and carboplatin treatments with or without esomeprazole for 72 h by using MTT
assay on A549 cell line. (A) Cisplatin and esomeprazole combination, *** P < 0.001 when compared to cisplatin treatment alone. (B)
Carboplatin and esomeprazole combination, *** P < 0.001 when compared to carboplatin treatment alone.
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Table. Combination index values were calculated for 250 µM esomeprazole in combination with various concentrations of cisplatin and
carboplatin.

250 µM
esomeprazole

Treatment

Combination index

6.25% TDC cisplatin

0.04 ± 0.01

12.5% TDC cisplatin

0.08 ± 0.01

25% TDC cisplatin

0.15 ± 0.02

50% TDC cisplatin

0.20 ± 0.05

100% TDC cisplatin

0.28 ± 0.10

200% TDC cisplatin

0.54 ± 0.17

6.25% TDC carboplatin

0.16 ± 0.05

12.5% TDC carboplatin

0.24 ± 0.01

25% TDC carboplatin

0.37 ± 0.04

50% TDC carboplatin

0.65 ± 0.09

100% TDC carboplatin

0.93 ± 0.31

200% TDC carboplatin

0.50 ± 0.09

3.2. Monitorization of cell death by a real-time
cytotoxicity assay
The cytotoxic effects of carboplatin and cisplatin combined
with three different doses of esomeprazole were assessed
in real time for 72 h by analyzing impedance produced
by the A549 cells (Figure 3). All doses of cisplatin had
antiproliferative effects except 100 TDC since only at
this dose was the final cell index value lower than the
initial value (cytotoxic effect). The combination with
esomeprazole resulted in an increase in antiproliferative
effects of cisplatin at lower doses. Although esomeprazole
itself had antiproliferative effects at 250 µM, the cell index
after 72 h was the same as the initial index. However, its
combination with cisplatin caused cytotoxic effects even
with doses as low as 25% TDC. Treatment alone with
carboplatin resided in an antiproliferative range at all
doses after 72 h. Similar to its combination with cisplatin,
esomeprazole increased the antiproliferative effects of
carboplatin at lower doses and 50% TDC and 100% TDC
combinations of carboplatin with 250 µM esomeprazole
demonstrated cytotoxic activity.
3.3. Assessment of apoptosis by M30 assay
Levels of M30 (an apoptosis marker) were measured in
the A549 cell line after 48 h of treatment with 100% TDC
cisplatin and 100% TDC carboplatin alone and their
combination with 250 µM esomeprazole to determine the
cell death mode. Cisplatin, esomeprazole + cisplatin, and
carboplatin increased M30 levels, suggesting cell death by
apoptosis. In contrast, no increase was observed in M30
levels in the esomeprazole + carboplatin combination
(Figure 4).

3.4. Fluorescence microscopic examination of cell death
We examined the effects of carboplatin and cisplatin
combination with esomeprazole microscopically to
determine cell death mode. We did not observe remarkable
Annexin-V-FITC staining after cisplatin and carboplatin
treatments alone (data not shown). However, there was
Annexin-V-FITC positivity in 250 µM esomeprazoletreated cells reflecting the partial proapoptotic effect
(Figure 5). Both Annexin-V-FITC and PI stainings were
observed in 250 µM esomeprazole combinations of 100%
TDC cisplatin and 100% TDC carboplatin. Pyknotic
nuclei were also observed in Hoechst 33342 staining in
both combinations, although a higher fraction of nuclei
were pyknotic in esomeprazole + cisplatin. The presence
of PI in cells with pyknotic nuclei suggests that these cells
had already lost their membrane integrity and underwent
secondary necrosis, which is considered as a late-stage
event in apoptosis (Figure 5).
3.5. SDS-PAGE and western blotting for confirmation of
apoptosis
PARP cleavage is considered one of the hallmarks of
apoptosis. Therefore, we performed western blotting
in order to determine whether PARP was cleaved after
carboplatin and cisplatin treatments and their combination
with esomeprazole. Our aim was to clarify the cell death
mode in carboplatin or cisplatin combinations with
esomeprazole, as PARP cleavage can be considered to be a
molecular marker of apoptosis. The results demonstrated
in Figure 6 were obtained from the same membrane.
Esomeprazole and carboplatin treatments alone caused
a slight cleavage of PARP. However, cisplatin alone and
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Figure 3. Cell viability was monitored for 72 h with real-time cytotoxicity assay. A549 cells were incubated with cisplatin alone (A),
cisplatin in combination with increasing doses of esomeprazole (B–D), carboplatin alone (E), and carboplatin in combination with
increasing concentrations of esomeprazole (62.5, 125, and 250 µM) (F–H). Note the shift from antiproliferative effect to cytotoxic effect
of the lower doses of drugs when used in combination with 250 µM esomeprazole.
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M30 antigen (U/L )

2000
1500
1000
500
0

Figure 4. M30 levels (U/L) were measured 48 h after treatment
with cisplatin (100% TDC), carboplatin (100% TDC), and their
combinations with esomeprazole (250 µM). M30 detection was
performed in the cell culture medium by ELISA as explained in
Section 2. Note the apoptosis-inducing effect of cisplatin, but
not of carboplatin, which may induce another type of cell death
modality.

Figure 5. Fluorescence images of cells were taken after staining with Hoechst dye 33342 (upper row), Annexin-V-FITC (middle row),
and PI (lower row) following treatment with esomeprazole (250 µM), cisplatin (100% TDC) + esomeprazole (250 µM) combination, and
carboplatin (100% TDC) + esomeprazole (250 µM) combination for 12 h. White arrows denote early-stage apoptotic nuclei while yellow
arrows denote late-stage apoptotic nuclei. Thus, a mixture of early- and late-stage apoptotic nuclei is seen in the treated population.

its combination with esomeprazole clearly resulted in
PARP cleavage. Cleaved PARP levels did not change in
carboplatin and esomeprazole combinations despite
there being a slight increase in the 250 µM esomeprazole

combination that might be attributed to the combined
effects of individual carboplatin and esomeprazole
treatments.
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Figure 6. Changes in cleaved PARP levels determined by western blotting 24 h after 100% TDC cisplatin or carboplatin treatments in
combination with increasing concentrations of esomeprazole (62.5, 125, and 250 µM). β-Actin was used as the loading control.

4. Discussion
The studies that revealed the presence of a distinct pH
gradient between the intracellular and extracellular
medium and the major role of the acidic microenvironment
and acidic vesicles in the resistance of tumor cells to
cytotoxic drugs brought forward the idea to increase
chemosensitivity by changing the conditions of tumor
microenvironment (Tannock and Rotin, 1989; Simon et
al., 1994; Altan et al., 1998; Martinez-Zaguilan et al., 1999;
Raghunand et al., 1999a, 1999b; Izumi et al., 2003; Mahoney
et al., 2003). Our hypothesis was based on overcoming
the pH gradients that were demonstrated as one of the
reasons for chemoresistance with the usage of PPIs. One
of the PPIs, esomeprazole, was used in this study to inhibit
V-ATPases that are known to be highly expressed in
tumor cells (Tannock and Rotin, 1989; Martinez-Zaguilan
et al., 1999; Nishi and Forgac, 2002; Torigoe et al., 2002;
Sennoune et al., 2004). There are examples of clinical trials
aiming to increase the effectiveness of chemotherapy via
a combination of a basic drug such as doxorubicin and a
PPI. Pantoprazole in combination with doxorubicin was
concluded to be feasible in a phase I trial in various solid
tumors not including lung cancer (Brana et al., 2014).
Real-time cytotoxicity data were obtained from the
xCELLigence system that gives information about whether
a compound has antiproliferative, cytostatic, or cytotoxic
effects at a particular dose and time point. In general,
62.5 µM and 125 µM esomeprazole combinations with
carboplatin and cisplatin modified the antiproliferative
effects of these drugs slightly. Importantly, despite the 250
µM concentration of esomeprazole being cytostatic alone,
its combination with cisplatin demonstrated cytotoxic
effects at doses as low as 25% TDC. Combination with
250 µM esomeprazole also modified the cytostatic
effect of 50% TDC cisplatin treatment alone to become
cytotoxic. Such a similar potentiation effect was observed
when cisplatin was used in combination with another
PPI, bafilomycin (Murakami et al., 2001). Using a lower
dosage in carboplatin and cisplatin combinations with
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esomeprazole might have implications in preventing the
side effects of these chemotherapeutics. Furthermore,
the presence of a synergistic interaction at especially
low-dose combinations of 250 µM esomeprazole and
cisplatin or carboplatin supports this approach. Cisplatin
in combination with 250 µM esomeprazole generated very
strong or strong synergism in the 6.25%–100% TDC dose
range (Chou, 2006). Taken together, combinations of 250
µM esomeprazole and 25%–100% TDC cisplatin would be
both cytotoxic and strongly synergistic.
Esomeprazole in combination with paclitaxel,
docetaxel, gemcitabine, and vinorelbine did not show
cytotoxic effects in the A549 lung cancer cell line.
However, apparent and statistically significant cytotoxic
effects were observed in combinations of cisplatin and
carboplatin. In a recent phase II clinical trial conducted
with metastatic breast cancer patients, it was proven that
esomeprazole enhanced the effects of docetaxel followed
by cisplatin combination treatment and improved the
overall survival without any toxic effects (Wang et al.,
2015). Luciani et al. (2004) showed a significant increase
in chemosensitivity when omeprazole, another PPI, was
used 24 h prior to treatment with chemotherapeutic
agents in solid tumor cell lines other than lung cancer
(22 melanoma, 2 colon adenocarcinoma, 2 breast
cancer, 2 ovarian cancer, 1 endometrium cancer, and 1
T-lymphoblastoid cell lines). In contrast to our study,
drug sensitivity disappeared when omeprazole was used
simultaneously with chemotherapeutic agents. This
finding suggests that there might be differences between
cancer types and chemotherapeutic agents regarding the
V-ATPase response to PPIs.
An increase in cell death was observed in combinations
of weakly basic chemotherapeutic agents, cisplatin and
carboplatin, with esomeprazole. However, the same
outcome was not observed in combinations with other
weakly basic chemotherapeutics, namely gemcitabine
and vinorelbine, which suggests that the enhanced
cytotoxicity observed in cisplatin and carboplatin does
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not solely depend on acidic or basic properties of the
chemotherapeutic agents (Luciani et al., 2004; Booker et
al., 2014).
After demonstrating the cell death-inducing effect of
esomeprazole combination with cisplatin and carboplatin,
we tried to determine the cell death mode by measuring
cleaved cytokeratin 18 (M30) levels by using ELISA.
Cisplatin alone and in combination with esomeprazole
elevated M30 levels, suggesting apoptosis. The M30
increase in carboplatin treatments suggests apoptotic
cell death; however, the carboplatin combination with
esomeprazole lowered M30 levels, which illustrates a shift
from apoptosis to another cell death modality. Western
blotting confirmed the findings in the M30 assay for
cisplatin and esomeprazole combinations with higher
M30 levels in combination treatments corresponding to a
higher amount of cleaved PARP, both suggesting enhanced
apoptosis in cisplatin and esomeprazole combinations. On
the other hand, PARP cleavage also occurred in carboplatin
and esomeprazole combinations, although it was not as
pronounced as in cisplatin combinations.
We performed fluorescence microscopy to decide
conclusively about the cell death mode in both cisplatin and
carboplatin combinations with 250 µM esomeprazole. An
early apoptotic event, translocation of phosphatidylserine
to the extracellular layer of the cell membrane, was
visualized by Annexin-V-FITC staining 12 h after

treatment. Annexin-V-FITC staining and the presence of
pyknotic nuclei in both combinations supported apoptotic
cell death. PI positivity in the majority of the cells also
indicated that secondary necrosis following apoptosis
had predominantly occurred at this time point. Thus,
the findings from fluorescence microscopy support the
results obtained from western blotting for cisplatin and
carboplatin combinations with 250 µM esomeprazole to
trigger apoptotic cell death, but pyknosis and Annexin-V
positivity was much more apparent with the combination
of cisplatin and esomeprazole. This finding, combined
with the unaffected M30 levels after carboplatin and
esomeprazole combination, leads to the conclusion that
apoptosis might not be the only cell death modality
induced by carboplatin and esomeprazole combination.
The results of this study indicate that esomeprazole
increases the sensitivity of tumors to chemotherapeutics
and can protect from the side effects arising because of high
doses of chemotherapeutics. Further in vivo investigation
is needed to elucidate the mechanisms by which cisplatin
and esomeprazole combinations can distinctively lead to a
stronger cytotoxic activity in the A549 nonsmall-cell lung
cancer cell line and other lung cancer cell lines.
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